GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eurobio Scientific (XPAR:ALERS) » Definitions » Cash-to-Debt

Eurobio Scientific (XPAR:ALERS) Cash-to-Debt : 0.88 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Eurobio Scientific Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Eurobio Scientific's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.88.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Eurobio Scientific couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Eurobio Scientific's Cash-to-Debt or its related term are showing as below:

XPAR:ALERS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.38   Med: 1.04   Max: 6.26
Current: 0.88

During the past 13 years, Eurobio Scientific's highest Cash to Debt Ratio was 6.26. The lowest was 0.38. And the median was 1.04.

XPAR:ALERS's Cash-to-Debt is ranked worse than
64.54% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 1.91 vs XPAR:ALERS: 0.88

Eurobio Scientific Cash-to-Debt Historical Data

The historical data trend for Eurobio Scientific's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Eurobio Scientific Cash-to-Debt Chart

Eurobio Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 2.16 6.26 0.75 0.88

Eurobio Scientific Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.26 7.99 0.75 0.66 0.88

Competitive Comparison of Eurobio Scientific's Cash-to-Debt

For the Medical Devices subindustry, Eurobio Scientific's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eurobio Scientific's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eurobio Scientific's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Eurobio Scientific's Cash-to-Debt falls into.



Eurobio Scientific Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Eurobio Scientific's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Eurobio Scientific's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eurobio Scientific  (XPAR:ALERS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Eurobio Scientific Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Eurobio Scientific's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Eurobio Scientific (XPAR:ALERS) Business Description

Traded in Other Exchanges
Address
63-65 Boulevard Massena, Paris, FRA, 75013
Eurobio Scientific is one of the leading providers of specialty in vitro diagnostics and life-science solutions. The product portfolio includes Tetanos Quick Stick, BJI InoPlex, AlloMap, and TEDAC Consortium.

Eurobio Scientific (XPAR:ALERS) Headlines

No Headlines